Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Azenta, Inc. - Common Stock
(NQ:
AZTA
)
34.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Azenta, Inc. - Common Stock
< Previous
1
2
3
4
Next >
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
March 27, 2025
Shareholders of Azenta would probably like to forget the past six months even happened. The stock dropped 23.7% and now trades at $37.66. This might have investors contemplating their next move.
Via
StockStory
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
March 26, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...
Via
StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
March 25, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.
Via
StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
March 21, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.
Via
StockStory
A Glimpse Into The Expert Outlook On Azenta Through 4 Analysts
February 06, 2025
Via
Benzinga
Earnings Scheduled For February 5, 2025
February 05, 2025
Via
Benzinga
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
March 18, 2025
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.
Via
StockStory
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
March 13, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,...
Via
StockStory
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
March 12, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.
Via
StockStory
1 Small-Cap Stock with Exciting Potential and 2 to Brush Off
March 11, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
Topics
Supply Chain
Exposures
Supply Chain
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
A Look Ahead: Azenta's Earnings Forecast
November 11, 2024
Via
Benzinga
Decoding 5 Analyst Evaluations For Azenta
July 02, 2024
Via
Benzinga
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
March 11, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...
Via
StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
March 05, 2025
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
What To Expect From Fortrea’s (FTRE) Q4 Earnings
March 02, 2025
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
Via
StockStory
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
February 24, 2025
Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
The Analyst Landscape: 7 Takes On Azenta
May 09, 2024
Via
Benzinga
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
February 19, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.
Via
StockStory
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
February 18, 2025
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know.
Via
StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
February 12, 2025
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for.
Via
StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
February 09, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect.
Via
StockStory
Azenta’s (NASDAQ:AZTA) Q4 Sales Top Estimates
February 05, 2025
Life sciences company Azenta (NASDAQ:AZTA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, but sales fell by 4.4% year on year to $147.5 million. Its non-GAAP profit of $0.05 per...
Via
StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
February 05, 2025
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
Via
Benzinga
Illumina (ILMN) Reports Earnings Tomorrow: What To Expect
February 05, 2025
Genomics company Illumina (NASDAQ:ILMN) will be reporting results tomorrow after the bell. Here’s what investors should know.
Via
StockStory
IQVIA (IQV) Q4 Earnings Report Preview: What To Look For
February 05, 2025
Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for.
Via
StockStory
Quantum Computing, BlackBerry And Lucid Group Are Among Top Mid Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
December 22, 2024
The top nine mid-cap stocks from the last week are: Quantum Computing Inc., BlackBerry Limited, IonQ, Inc., Rigetti Computing, Inc., SoundHound AI, Inc., Xometry, Inc., Lucid Group, Inc., Oklo Inc.,...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday
November 20, 2024
Via
Benzinga
AZTA Stock Earnings: Azenta Beats EPS, Beats Revenue for Q3 2024
August 06, 2024
AZTA stock results show that Azenta beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.
Via
InvestorPlace
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Robotics Stocks
May 14, 2024
Despite the promises of the robotics industry, there are key robotics stocks to sell as the market remains volatile.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.